End date of the last completed financial year: 2018-12-31
|Government Institution||Funding Received in Last Financial Year||Funding Expected in Current Financial Year|
|Australian Government (DFAT)||$2,822,678.00||Yes|
|German Government (BMBF)||$467,101.00||Yes|
|National Institutes of Health (NIH)||$30,900.00||Yes|
|Netherlands Government (OTA)||$3,760,587.00||Yes|
|Swiss Government (DEZA/SDC)||$1,616,834.00||Yes|
|UK Government (Department of Health)||$5,031,648.00||Yes|
|UK Government (DFID)||$14,986,801.00||Yes|
|US Government (USAID)||$1,054,178.00||Yes|
Route de Pré-Bois 20, ICC
Cointrin, Geneva 1216
Web address: www.mmv.org
Matthew Doherty, Manager, Donor and Stakeholder Relations
MMV Medicines for Malaria Venture is not a subsidiary of any other parent companies.
MMV Medicines for Malaria Venture is not a coalition.
The activities of MMV Medicines for Malaria Venture are not controlled or directed by another person or organization with a direct interest in the outcome of this undertaking.
MMV Medicines for Malaria Venture does not have any subsidiaries that could have a direct interest in the outcome of the undertaking
Paul Moen | Public offices held
Firm: Earnscliffe Strategy Group Inc.